Clinical Trial SuccessThe plozasiran pipeline-in-a-drug strategy is underscored by positive Phase III PALISADE study results in familial chylomicronemia syndrome.
Pipeline DevelopmentThe extra-hepatic pipeline expansion shows visible progress in high-value programs like ARO-RAGE, ARO-DM1, ARO-DUX4, and ARO-INHBE.
Strategic FinancingArrowhead Pharmaceuticals announced securing $500M strategic financing facility with flexible 7-year repayment structure, which supports its aggressive pipeline expansion.